Catherine E. Muehlenbein

Also affiliated with Loxo Oncology at Lilly (United States)

MedicineEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies”.

Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies

Acta Haematologica(2024)10.1159/000539587

N/A

0.104DataRank · unranked

1 citations

Catherine C. Coombs, Nirav N. Shah, Wojciech Jurczak, Jennifer A. Woyach, Chan Y. Cheah +16 more

Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001

Journal of Thoracic Oncology(2022)10.1016/j.jtho.2022.02.004

N/A

0DataRank · unranked

57 citations

Christian Rolfo, Alexander Drilon, Mario E. Lacouture, Benjamin Besse, Kōichi Goto +10 more